Overview Satisfaction and Compliance of Risedronate in PMO Status: Completed Trial end date: 1969-12-31 Target enrollment: Participant gender: Summary Compare subject satisfaction of once a week dosing of 35 mg Risedronate to once daily dosing of 5 mg Risedronate in postmenopausal osteoporotic women. Secondary objectives are to measure compliance (50 % drug taken), and persistence. Phase: Phase 4 Details Lead Sponsor: SanofiTreatments: Risedronate SodiumRisedronic Acid